Predicting Patient Survival in Oncology: Is it Time to Take a New Path?

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Oxnard GR, Morris MJ, Hodi FS, Baker LH, Kris MG, Venook AP, et al. When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst. 2012;104:1534–41.

    Article  Google Scholar 

  2. 2.

    de la Torre-Aláez M, Jordán-Iborra C, Casadei-Gardini A, Bilbao JI, Rodriguez-Fraile M, Sancho L, et al. The pattern of progression defines post-progression survival in patients with hepatocellular carcinoma treated with SIRT. Cardiovasc Interv Radiol. 2020;12:1–8.

    Google Scholar 

  3. 3.

    Reig M, Rimola J, Torres F, Darnell A, Rodriguez-Lope C, Forner A, et al. Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. Hepatol. 2013;58:2023–31.

    CAS  Article  Google Scholar 

  4. 4.

    Rincón JO, Regi AR, Leyte MG, Martín LC, Pascual RP, Farto JCA. Hepatic supraselective radioembolization, today and new horizons. Eur J Nucl Med Mol Imaging. 2019;46:2412–3.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Jean-Francois H. Geschwind.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Nezami, N., Geschwind, J.H. Predicting Patient Survival in Oncology: Is it Time to Take a New Path?. Cardiovasc Intervent Radiol (2020). https://doi.org/10.1007/s00270-020-02553-y

Download citation